Literature DB >> 25394088

Quality of life of people living with HIV, preliminary results from IANUA (Investigation on Antiretroviral Therapy) study.

Alberto Venturini1, Barbara Giannini2, Marcello Montefiori3, Antonio Di Biagio4, Giovanni Mazzarello4, Giovanni Cenderello1, Mauro Giacomini5, Caterina Merlano6, Patrizia Orcamo6, Maurizio Setti7, Claudio Viscoli4, Giovanni Cassola1.   

Abstract

INTRODUCTION: The introduction of combined antiretroviral treatment (cART) has reduced HIV-associated morbidity and mortality, and changed the patients' perspective of life. As a result, Health Related Quality of Life (HRQOL) has become a crucial clinical issue.
OBJECTIVE: Assessment of HRQOL in a sample of Italian patients from IANUA study. Investigate correlation between CD4 cell counts, viral load and changes in HRQOL.
MATERIALS AND METHODS: EQ-5D-3L self-reported questionnaire has been used in the evaluation of HRQOL. It assesses five dimensions: "mobility," "self care," "usual activities," "pain/discomfort" and "anxiety/depression." Each dimension has three levels: no problems, some problems and extreme problems. In addition, it includes a Visual Analogue Scale (VAS) where one's own health "today" is rated from 0 "worst imaginable health" to 100 "best imaginable health." The respondents provide information on marital status, education, employment/unemployment, other treatments used in addition to HAART (1,2,3,4,5 or more) and number of hospitalizations due to HIV/AIDS.
RESULTS: 684 patients completed the questionnaire: 231 females and 453 males. The mean age of the sample was 51 years (range 21-78). The mean VAS score was 69.9. 558 patients (81.5%) reported no problems in mobility. 642 patients (93.5%) had no problems in self care. 423 patients (61.8%) had no pain/discomfort while 219 had some problems. 326 patients (46.1%) had some problems in anxiety/depression.
CONCLUSIONS: The analysis of self-reported questionnaires indicates that HRQOL in our sample group is not deeply affected by HIV/AIDS. The dimensions that are affected in the least are "mobility" and "self care" while the major problem is "anxiety/depression" with half of the sample reporting moderate or high level.

Entities:  

Year:  2014        PMID: 25394088      PMCID: PMC4224913          DOI: 10.7448/IAS.17.4.19581

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


  4 in total

Review 1.  Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update.

Authors:  Hugo Ribeiro Zanetti; Leonardo Roever; Alexandre Gonçalves; Elmiro Santos Resende
Journal:  Curr Atheroscler Rep       Date:  2018-02-08       Impact factor: 5.113

2.  Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria.

Authors:  Olurotimi Adejumo; Bibilola Oladeji; Onoja Akpa; Kay Malee; Olusegun Baiyewu; Adesola Ogunniyi; Scott Evans; Baiba Berzins; Babafemi Taiwo
Journal:  Int J STD AIDS       Date:  2015-09-18       Impact factor: 1.359

3.  Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe.

Authors:  Karine Chevreul; Coralie Gandré; Karen Berg Brigham; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; László Gulácsi; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Ulf Persson; Giovani Fattore
Journal:  Eur J Health Econ       Date:  2016-04-12

4.  A novel Bursin-like peptide as a potential virus inhibitor and immunity regulator in SPF chickens infected with recombinant ALV.

Authors:  Yukun Zeng; Zuxin Gong; Binbin Wu; Wenchao Guan; Shenyi Yu; Yajuan An; Rongbin Lu; Jinrong Zhao; Yijian Wu; Yifan Huang; Xiaoping Wu
Journal:  BMC Vet Res       Date:  2019-12-10       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.